9,983 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by Keybank National Association OH

Keybank National Association OH purchased a new position in NewAmsterdam Pharma (NASDAQ:NAMS) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 9,983 shares of the company’s stock, valued at approximately $257,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Handelsbanken Fonder AB bought a new position in NewAmsterdam Pharma during the 4th quarter valued at about $4,816,000. TimesSquare Capital Management LLC lifted its stake in NewAmsterdam Pharma by 250.9% during the 4th quarter. TimesSquare Capital Management LLC now owns 895,574 shares of the company’s stock valued at $23,016,000 after acquiring an additional 640,329 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in NewAmsterdam Pharma during the 4th quarter valued at about $80,000. abrdn plc lifted its stake in NewAmsterdam Pharma by 38.7% during the 4th quarter. abrdn plc now owns 179,060 shares of the company’s stock valued at $4,602,000 after acquiring an additional 50,000 shares during the period. Finally, Jennison Associates LLC lifted its stake in NewAmsterdam Pharma by 291.9% during the 4th quarter. Jennison Associates LLC now owns 3,998,541 shares of the company’s stock valued at $102,763,000 after acquiring an additional 2,978,263 shares during the period. Institutional investors own 89.89% of the company’s stock.

Insiders Place Their Bets

In other news, Director James N. Topper bought 4,005 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The stock was purchased at an average price of $21.02 per share, with a total value of $84,185.10. Following the completion of the acquisition, the director now directly owns 3,012,434 shares of the company’s stock, valued at $63,321,362.68. This trade represents a 0.13 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the sale, the chief accounting officer now directly owns 15,000 shares of the company’s stock, valued at $305,550. This trade represents a 90.91 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 554,927 shares of company stock valued at $13,446,287. 19.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

NAMS has been the subject of several research reports. UBS Group set a $41.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, March 3rd. HC Wainwright reaffirmed a “buy” rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Scotiabank increased their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Thursday, February 27th. Needham & Company LLC reduced their target price on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a report on Thursday, February 27th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $43.33.

NewAmsterdam Pharma Price Performance

NAMS opened at $22.88 on Wednesday. The business’s 50-day moving average is $22.10 and its two-hundred day moving average is $20.63. NewAmsterdam Pharma has a 1 year low of $15.19 and a 1 year high of $27.29. The firm has a market capitalization of $2.51 billion, a PE ratio of -8.80 and a beta of -0.04.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The business had revenue of $12.77 million during the quarter, compared to the consensus estimate of $3.30 million. As a group, sell-side analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.